Therapy News and Research

RSS

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

For most the ability to see is often taken for granted. But for the thousands diagnosed with ocular melanoma, the fear of losing their eyesight or even worse, their lives, is an all too real possibility. Ocular melanoma is seen as a rare form of cancer, with approximately two thousand new diagnoses per year.

11 Aug 2015

Researchers create new cell screening method for immunotherapy cancer treatments

Researchers have created a new method for screening cells used in immunotherapy cancer treatments, allowing high-performing immune system cells to be studied in isolation and potentially expanding the number of patients for whom the breakthrough treatment proves successful.

11 Aug 2015

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory today announced the commercialization of their HemosIL Rivaroxaban Testing Solution in Europe. The HemosIL Liquid Anti-Xa assay, when used in conjunction with HemosIL Rivaroxaban Calibrators and HemosIL Rivaroxaban controls offers an automated solution for measurement of rivaroxaban.

10 Aug 2015

Gamida Cell reaches agreements with FDA and EMA regarding NiCord Phase III study design outline

Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the company has reached agreements with the FDA and EMA regarding the Phase III study design outline of NiCord.

10 Aug 2015

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

Constraint-induced movement therapy trialled in patients’ homes

A randomised trial from Germany has attempted to turn constraint-induced movement therapy into a cost-effective home-based treatment for stroke survivors.

7 Aug 2015

Flowonix Medical's new Patient Therapy Controller approved for market release

Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.

7 Aug 2015

TSRI study explores bacterial enzyme that may help people to quit smoking

A new study from scientists at The Scripps Research Institute explores a bacterial enzyme that might be used as a drug candidate to help people quit smoking.

7 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

Scientists publish new important clues about marrow fat

While most of us worry about the fat cells building up on the fleshy parts of our bodies, scientists have started to pay serious attention to another kind of fat cell deep inside our bones, in what's called the marrow.

7 Aug 2015

Brili launches new app for families with ADHD kids at 2015 APA Convention

Brili Inc., the company that creates technology to help kids succeed, today launches an app for families challenged with ADHD at the 2015 APA Convention. The conference will feature over thirty different presentations focused on ADHD, indicative of the pervasiveness of a condition affecting millions of children. Brili will be showcasing how their app can help families manage the challenges of ADHD during the hectic and challenging back to school crunch.

7 Aug 2015

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin.

7 Aug 2015

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Women who receive a shorter course of whole breast radiation therapy for early stage disease experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment, researchers report from The University of Texas MD Anderson Cancer Center.

7 Aug 2015

Scientists develop biosensor to measure abnormal activity of cell 'fuel' carrier

To be able to function, cell mitochondria import "fuel" using a carrier, the Mitochondrial Pyruvate Carrier (MPC). In order to determine whether the MPC is still functional in malignant cells, the team of Professor Jean-Claude Martinou, at the University of Geneva, Switzerland, has just developed a biosensor to measure its live activity.

7 Aug 2015

NFIX protein drives NSC differentiation toward oligodendrocytes

An international team of researchers has shown that NFIX, a protein that regulates neuronal stem cell activity (NSC), also has a role in driving NSC differentiation toward oligodendrocytes, a type of glial cell. These cells produce the myelin that surrounds and protects neurons.

7 Aug 2015

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).

6 Aug 2015

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

Vtesse, Inc. announced preliminary results today from an open-label Phase 1 clinical trial with VTS-270 (a formulation of (2-hydroxypropyl)-beta-cyclodextrin) for treatment of Niemann-Pick Disease Type C (NPC) conducted by researchers at the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development.

6 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Therapy News and Research

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

Researchers create new cell screening method for immunotherapy cancer treatments

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Gamida Cell reaches agreements with FDA and EMA regarding NiCord Phase III study design outline

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Constraint-induced movement therapy trialled in patients’ homes

Flowonix Medical's new Patient Therapy Controller approved for market release

TSRI study explores bacterial enzyme that may help people to quit smoking

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Scientists publish new important clues about marrow fat

Brili launches new app for families with ADHD kids at 2015 APA Convention

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Scientists develop biosensor to measure abnormal activity of cell 'fuel' carrier

NFIX protein drives NSC differentiation toward oligodendrocytes

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Vtesse reports preliminary results from VTS-270 Phase 1 trial for treatment of Niemann-Pick Disease Type C

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News